What is the price target for 1MDGL stock?
24 analysts have analysed 1MDGL.MI and the average price target is 557.23 EUR. This implies a price increase of 35.02% is expected in the next year compared to the current price of 412.7.
MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) Forecast, Price Target & Analyst Ratings
BIT:1MDGL • US5588681057
Current stock price
412.7 EUR
+33.3 (+8.78%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MADRIGAL PHARMACEUTICALS INC (1MDGL.MI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Feb 19, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.92
- Revenue Estimate
- 318.74M
Price Target Details & History
Consensus Price Target and Range
Mean target
€557.23
Upside
+ 35.02%
From current price of €412.70 to mean target of €557.23, Based on 24 analyst forecasts
Low
€433.34
Median
€539.75
High
€851.54
Price Target Revisions
1 Month
25.56%
3 Months
25.56%
Price Target Summary
24 Wall Street analysts provided a forecast for the next 12 months for 1MDGL.MI. The average price target is 557.23 EUR. This implies a price increase of 35.02% is expected in the next year compared to the current price of 412.7.
The average price target has been revised upward by 25.56% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.67%
1MDGL.MI was analyzed by 24 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about 1MDGL.MI.
In the previous month the buy percentage consensus was at a similar level.
1MDGL.MI was analyzed by 24 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Feb 19, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.92
- Revenue Estimate
- 318.74M
- Revenue Q2Q
- 208.50%
- EPS Q2Q
- 66.08%
- Number of Analysts
- 19
Next Earnings Revisions
Revenue (1 Month)
0.27%
Revenue (3 Months)
0.27%
EPS (1 Month)
29.53%
EPS (3 Months)
29.53%
Next Earnings Summary
1MDGL.MI is expected to report earnings on 2/19/2026. The consensus EPS estimate for the next earnings is -0.92 EUR and the consensus revenue estimate is 318.74M EUR.
The next earnings revenue estimate has been revised upward by 0.27% in the past 3 months.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 180.133M | 964.47M 435.42% | 1.489B 54.39% | 2.172B 45.87% | 2.99B 37.66% | 4.022B 34.52% | 4.94B 22.82% | 5.449B 10.30% | 6.134B 12.57% | 6.025B -1.78% | |||
| EBITDA YoY % growth | -293.13M -21.08% | -379.969M -29.62% | -496.779M -30.74% | -300.298M 39.55% | 34M 111.32% | 447.42M 1,215.94% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -293.6M -21.07% | -380.496M -29.60% | -497.875M -30.85% | -255.383M 48.71% | 19.977M 107.82% | 499.55M 2,400.63% | 1.172B 134.61% | 1.914B 63.31% | 2.745B 43.42% | 3.251B 18.43% | 3.83B 17.81% | 3.664B -4.33% | |
| Operating Margin | N/A | N/A | -276.39% | -26.48% | 1.34% | 23.00% | 39.20% | 47.59% | 55.57% | 59.66% | 62.44% | 60.81% | |
| EPS YoY % growth | -17.23 -17.93% | -19.94 -15.73% | -22.11 -10.88% | -10.95 50.49% | 1.05 109.61% | 17.85 1,596.75% | 38.24 114.18% | 57.53 50.46% | 76.00 32.11% | 134.04 76.37% | 166.79 24.43% | 187.67 12.52% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.92 66.08% | -0.85 74.39% | 0.30 115.85% | 1.13 122.77% | 1.99 316.55% | 5.37 730.97% | 8.58 2,748.58% | 11.33 903.00% | 14.10 608.51% |
| Revenue Q2Q % growth | 318.74M 208.50% | 312.08M 127.38% | 357.62M 68.05% | 396.41M 37.99% | 435.99M 36.79% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -82.199M -24.73% | -19.541M 75.24% | 20.287M 143.68% | 35.953M 131.86% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.036M 76.06% | -24.639M 68.93% | 5.7M 112.08% | 28.048M 124.61% | 53.792M 435.45% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
41.07%
EPS Next 5 Year
35.70%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
130.48%
Revenue Next 5 Year
86.68%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
41.27%
EBIT Next 5 Year
N/A
MADRIGAL PHARMACEUTICALS INC / 1MDGL.MI Forecast FAQ
Can you provide the upcoming earnings date for MADRIGAL PHARMACEUTICALS INC?
MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) will report earnings on 2026-02-19, before the market open.
What are the consensus estimates for MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) next earnings?
The consensus EPS estimate for the next earnings of MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) is -0.92 EUR and the consensus revenue estimate is 318.74M EUR.
What is the expected long term growth rate for 1MDGL stock?
The expected long term growth rate for MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) is 130.48%.